STP Virtual Continuing Education Courses

Home / Meetings / Annual Meetings / STP Virtual Continuing Education Courses

The Society of Toxicologic Pathology is offering three continuing education courses virtually in 2022. These programs have been approved for 4.00 hours of continuing education credit in jurisdictions that recognize RACE approval. All course registrants will also be able to download the course book a week prior to each webinar.

This program has been approved for 4.00 hours of continuing education credit in jurisdictions that recognize RACE approval.

Toxicologic Pathology and Risk Assessment of Environmental Exposures

Friday, September 16, 2022, 12:00 Noon–3:45 PM EDT

Co-Chairs: Arun K. Pandiri, BVSc&AH, MS, PhD, DACVP, DABT, NIEHS/NTP; and Maria L.Z. Dagli, DVM, MS, PhD, Universidade de São Paulo

Environmental toxicologic pathology is a specialized area that addresses the effects of contaminants and pollutants on human, animal, and ecological health. The common animal models to examine the potential hazards associated with environmental exposures include rodents, birds, amphibians, fish, and worms. The health hazards frequently resulting from environmental xenobiotic exposures include metabolic diseases and cancer. This session will aim to examine the common toxicologic pathology lesions and the regulatory assessments related to endocrine disruption and cancer. In addition, the use of adverse outcome pathways to understand disease and environmental risk assessment may also be discussed where ever it is appropriate.

Risk Assessment Approaches in Environmental Toxicology
George M. Woodall Jr., PhD, US EPA

A Toxicologist’s Perspective on Neuroendocrine Disruption Due to Environmental Exposures
Sue Marty, PhD, DABT, Dow Chemical Company

An Overview of Fish and Frog Assays Used in Endocrine Toxicity Research
Jeffrey C. Wolf, DVM, DACVP, EPL, Inc.

Filling Chemical Toxicity Data Gaps Using High-Throughput Integrated Models: Zebrafish as a Case Study
Robyn L. Tanguay, PhD, Oregon State University

Access Materials

Past Course(s)

This program has been approved for 4.00 hours of continuing education credit in jurisdictions that recognize RACE approval.

Optimizing Toxicologic Pathology Data: Fundamental Concepts and Recommended Practices

(Sponsored by the American College of Toxicology)

Friday, August 26, 2022, 12:00 Noon–3:45 PM EDT

Co-Chairs: Daniel J. Patrick, DVM, DACVP, DABT, Eli Lilly & Company; and Noel D. Horton, PhD, DABT, Inotiv

It is well known that successful preclinical safety assessment studies depend on reliable and accurate data, which usually include critical contributions from anatomic and clinical pathology. There are numerous pathology publications that provide insights and recommendations that reliably improve pathology data and overall study outcomes when implemented. This Continuing Education course will present 10 of the most important pathology-related concepts, with practical recommendations that toxicologists can utilize in their preclinical studies. These concepts include using recommended anatomic and clinical pathology study designs, communicating information with the study pathologist before the evaluation, understanding what constitutes a properly trained toxicologic pathologist, following recommended histopathology evaluation practices, appropriately determining the adversity of pathology data, using pathology diagnostic terminology that is globally harmonized and Standard for Exchange of Nonclinical Data (SEND) compliant, knowing when and when not to use pathology historical control data, implementing pathology quality control measures such as pathology peer review, and following recommended pathology reporting practices. This course will be presented by globally recognized toxicologic pathologists who have actively promoted and authored publications on these topics.

Recommended Anatomic and Clinical Pathology Study Designs and Prestudy Communication
Armando R. Irizarry, DVM, PhD, DACVP, Eli Lilly and Company

Prudent Practices for Prepping Pathologists, Handling Histopathology, and Assigning Adversity
Brad Bolon, DVM, MS, PhD, DACVP, DABT, ATS, FIATP, FRCPath, GEMpath Inc.

SENDing the Pathology Data We Have INHAND and Factors to Consider When Using Pathology Historical Control Data
Charlotte M. Keenan, VMD, C.M. Keenan ToxPath Consulting

Histopathology Quality Control and the Reporting of Pathology Data and Interpretations
James D. Fikes, DVM, PhD, DABVT, DACVP, Biogen

Access Materials

This program has been approved for 4.00 hours of continuing education credit in jurisdictions that recognize RACE approval.

From Anticipated Immunomodulation to Safety Concern: Use of Immune Biomarkers in Preclinical Studies

Friday, August 12, 2022, 12:00 Noon–3:45 PM EDT

Co-Chairs: Caitlyn Carter, DVM, DACVP, Charles River Laboratories; and Michael Logan, DVM, PhD, DACVP, AbbVie

Biomarkers of the immune system are being applied to preclinical safety studies with increasing frequency as the availability of method and platform options continues to expand. This course will focus on the use of traditional and novel biomarkers of the immune system that are being used on preclinical safety studies. Practical considerations for their appropriate, and sometimes inappropriate use will be presented including biomarker selection, application in various preclinical settings, study design, sampling collection optimization (matrix, kinetics, timing and collection), and interpretative considerations. Method limitations, pitfalls to avoid, and successful implantation strategies will also be discussed with supporting case examples. Finally, topics related to immunology biomarker components specific to emerging novel therapeutic platforms (e.g., CD3 engagement, bispecific antibodies, cell and gene therapies) will be presented.

Overview and Considerations for the Use of Biomarkers of the Immune System in Preclinical Safety Studies
Adam Aulbach, DVM, DACVP, Inotiv

Getting It Right: The Correct Assays, Matrices, and Intervals Result in a Robust Data Set. Now…How Do We Interpret Them?
Erin Vaughan, PhD, AbbVie

Possible vs. Advisable: How Do We Optimally Use (and Not Abuse) Immunology Biomarkers in a Preclinical Setting?
Rob Caldwell, PhD, AbbVie

Platform Specific Considerations: What Biomarkers Provide the Best Value for My Specialized Target/Mechanism/Modality?
Danice Wilkins, PhD, MS, Charles River Laboratories

Access Materials

Continuing Education Chair:
Sanjeev Gumber, BVSc, MVSc, PhD, DACVP, Boehringer Ingelheim

Continuing Education Co-Chair:
Maria L.Z. Dagli, DVM, MS, DACVP, Universidade de São Paulo